NTII — Neurobiological Technologies Share Price
Last trade - 00:00- $0.00m
- -$3.25m
- $26.35m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | -0.18 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1405.3% | ||
| Return on Equity | 206.89% | ||
| Operating Margin | 72.21% | ||
Financial Summary
| Year End 30th Jun | Unit | 2005 | 2006 | 2007 | 2008 | 2009 | 2010E | 2011E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.1 | 12.34 | 17.67 | 14.76 | 26.35 | n/a | n/a | 56.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neurobiological Technologies, Inc. (NTI), was previously focused on developing investigational drugs to treat human diseases. On October 27, 2009, the Company’s stockholders approved the dissolution of the Company pursuant to a plan of complete liquidation and dissolution earlier approved by its board of directors on August 27, 2009 (the Plan of Dissolution). As a Company in dissolution, NTI was not allowed to carry on any business except for the purpose of winding down the business and affairs of the Company. On December 17, 2009, the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware (the Certificate of Dissolution). As of June 30, 2010, NTI retains an interest in an investigational drug called XERECEPT, which is a synthetic preparation of Corticotropin-Releasing Factor, a natural human peptide. XERECEPT is being developed by Celtic Pharma as a treatment for swelling around brain tumors and other cancer indications.
Directors
- Last Annual
- June 30th, 2009
- Last Interim
- December 17th, 2009
- Incorporated
- January 25th, 1994
- Public Since
- February 16th, 1994
- No. of Shareholders
- 200
- No. of Employees
- 4
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 27,019,805
- Address
- 2010 Crow Canyon Pl Ste 100, SAN RAMON, 94583-1344
- Web
- Phone
- +1 9253593247
- Auditors
- Odenberg Ullakko Muranishi & Co.
Similar to NTII
Acacia Diversified Holdings
Pink Sheets on Nasdaq
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 19:15 UTC, shares in Neurobiological Technologies are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Neurobiological Technologies last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Neurobiological Technologies share price has underperformed the S&P500 Index by -11.77% over the past year.
The overall consensus recommendation for Neurobiological Technologies is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Neurobiological Technologies does not currently pay a dividend.
Neurobiological Technologies does not currently pay a dividend.
Neurobiological Technologies does not currently pay a dividend.
To buy shares in Neurobiological Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Neurobiological Technologies had a market capitalisation of $0.00m.
Here are the trading details for Neurobiological Technologies:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NTII
Based on an overall assessment of its quality, value and momentum Neurobiological Technologies is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Neurobiological Technologies is $6.00. That is 599999900% above the last closing price of $0.00.
Analysts covering Neurobiological Technologies currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neurobiological Technologies. Over the past six months, its share price has underperformed the S&P500 Index by -99.91%.
As of the last closing price of $0.00, shares in Neurobiological Technologies were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Neurobiological Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Neurobiological Technologies' management team is headed by:
- Matthew Loar - CEO
- William Fletcher - DRC
- John Stuppin - DRC